Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    A new page revision label v3.5.4 was added to the history, replacing the previous v3.5.3. This indicates an update to the study record's revision history.
    Difference
    0.0%
    Check dated 2026-05-15T05:57:25.000Z thumbnail image
  4. Check
    28 days ago
    No Change Detected
  5. Check
    42 days ago
    Change Detected
    Summary
    Updates to the study record history view showing a newer submitted version (2026-04-21) and that the prior version number/revision (v3.5.2) was removed, with the change list referencing categories like Contacts/Locations and Study Status.
    Difference
    0.2%
    Check dated 2026-04-24T05:54:25.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2 to the record history. Removed Revision: v3.5.0 from the record history.
    Difference
    0.0%
    Check dated 2026-04-17T02:41:17.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    A new revision entry, v3.5.0, has been added to the history, and the entry for v3.4.3 has been removed.
    Difference
    0.0%
    Check dated 2026-03-19T05:30:56.000Z thumbnail image
  8. Check
    85 days ago
    Change Detected
    Summary
    Revision v3.4.3 was added and Revision v3.4.2 was removed from the version history.
    Difference
    0.0%
    Check dated 2026-03-12T00:29:16.000Z thumbnail image
  9. Check
    114 days ago
    Change Detected
    Summary
    Revision: v3.4.2 added to the history and the preceding notices about government funding lapse and operating status (v3.4.1) were removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-02-11T11:15:08.000Z thumbnail image

Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.